$0.28
Value $54M
HRTX and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$0.28
Value $54M
$144.46
Value $357B
Heron Therapeutics (HRTX) has a market value of $54M and Merck & Company (MRK) $357B. Over the last year, with dividends, HRTX moved -74.5% and MRK +60.0%. Dividend yield: HRTX none, MRK 2.35%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
HRTX$54M
MRK$357B
MRK is 6,663 times HRTX
Revenue, 12 months
HRTX$148M
MRK$67.4B
MRK is 455 times HRTX
Net income, 12 months
HRTX-$22M
MRK$2.5B
Operating margin
HRTX-5.7%
MRK–
ROIC
HRTX-15.4%
MRK3.9%
19.3 points apart
P/E
HRTX–
MRK145.6
Dividend yield
HRTX0.0%
MRK2.4%
2.4 points apart
5-year return
HRTX-97.4%
MRK+101.1%
198.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
HRTX-97.4%
MRK+101.1%
| Period | HRTXWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -74.5%Price -74.5% | +60.0%Price +55.5% |
| 3 years since November 16, 2023 | -69.6%-32.7% a yearPrice -69.6% | +55.2%+15.8% a yearPrice +41.6% |
| 5 years since November 15, 2021 | -97.4%-51.9% a yearPrice -97.4% | +101.1%+15.0% a yearPrice +72.6% |
| 10 years since November 16, 2016 | -98.6%-34.6% a yearPrice -98.6% | +228.0%+12.6% a yearPrice +141.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
HRTXHeron TherapeuticsMRKMerck & Company
| Price | $0.28 | $144.46 |
|---|---|---|
| Market value | $54M | $357B |
| Enterprise value (EV) | – | $401B |
| P/E | – | 145.6 |
| P/E, 5-year median | – | 14.8 |
| P/B | 13.9 | 8.0 |
| EV/EBIT | – | 84.3 |
| Free cash flow yield | – | 4.1% |
| Revenue, 12 months | $148M | $67.4B |
|---|---|---|
| Net income, 12 months | -$22M | $2.5B |
| Free cash flow, 12 months | -$14M | $14.7B |
| Earnings per share, 12 months | -$0.11 | $0.98 |
| Revenue growth, year on year | 7.4% | 1.3% |
| Revenue growth a year, past | +11.8%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | 71.5% | 71.8% |
|---|---|---|
| Operating margin | -5.7% | – |
| Net margin | -14.5% | 3.6% |
| ROIC | -15.4% | 3.9% |
| ROE | -214.8% | 5.2% |
| Cash | $23M | $9.7B |
|---|---|---|
| Total debt | – | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | -0.9× | 2.4× |
| Dividend yield | – | 2.4% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($357B) is about 6,663.3 times Heron Therapeutics ($54M), at today's prices.
Since November 16, 2016, HRTX's price moved -98.6% and MRK's +141.7%. With dividends: HRTX -98.6% (-34.6% a year), MRK +228.0% (+12.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Heron Therapeutics and 2.35% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
Over the last twelve months, the net margin was -14.5% for Heron Therapeutics and 3.6% for Merck & Company, and the operating margin -5.7% and –. Revenue was $148M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.